Loading...
01/11 11:26
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed picture. Financial performance shows improvement in operating loss and gross margin, but revenue declined YoY. The Q&A reveals confidence in future growth, but uncertainties remain, especially with cash management and leadership transition risks. The lack of a shareholder return plan and ongoing financial challenges temper optimism. Positive aspects include improved margins and strategic partnerships, but these are offset by revenue decline and leadership risks, resulting in a neutral sentiment.
Revenue $5 million, down $300,000 year-over-year (from $5.3 million). The decline was due to a block of catch-up revenues recognized in Q1 2024 for prior Medicare sales.
Adjusted Revenue (apples to apples comparison) $5 million in Q1 2025 compared to $4.8 million in Q1 2024, indicating operational growth when excluding prior year catch-up revenues.
Gross Margin (GAAP) 42.2%, up from 26.4% year-over-year. The increase was affected by the volume and mix of ReWalk products sold, which impacted fixed overhead leverage.
Adjusted Gross Margin (non-GAAP) 42.2% of revenue, compared to 33.7% in Q1 2024. Margins were below expectations due to transitional costs from moving production to a contract manufacturer.
Operating Expenses (GAAP) $7 million, down from $7.9 million year-over-year. The decrease was due to cost savings from site closures and integration of AlterG.
Adjusted Operating Expenses (non-GAAP) $6.7 million, compared to $7.3 million in Q1 2024. The improvement was primarily due to lower development costs from completed projects.
Operating Loss (GAAP) $4.9 million, improved from $6.5 million year-over-year.
Adjusted Operating Loss (non-GAAP) $4.6 million, compared to $5.5 million in Q1 2024, reflecting improved operational performance.
Cash and Equivalents $5.7 million at the end of Q1 2025, with no debt. An additional $500,000 was raised through an ATM facility post-Q1.
ReWalk 7 FDA Clearance: FDA clearance of the ReWalk 7, the next generation exoskeleton, was achieved.
ReWalk Rentals: 36 ReWalk rentals are currently underway, primarily in Germany, indicating strong future sales potential.
AlterG Growth: AlterG product line has grown by 19% and 17% in the last two quarters.
ReWalk Contract with BARMER: A contract with BARMER in Germany serves as a model for working with other insurers in the region.
Expansion of MyoCycle Distribution: Expansion of MyoCycle distribution rates has been noted, which synergizes with the field sales team.
Expense Reduction: A 25% reduction in operating loss was achieved in Q1 2025.
Cash Management Improvements: Collaboration with Medicare Administrative Contractors (MACs) is expected to lead to faster claims processing and payments.
Leadership Transition: Larry Jasinski announced his retirement midyear, with a smooth transition plan for a new CEO.
Revenue Decline: Q1 revenues were down $300,000 year on year, which may indicate challenges in maintaining consistent revenue growth.
Regulatory Challenges: The company relies on regulatory approvals, such as the FDA clearance for ReWalk 7, which can be unpredictable and may impact product availability.
Supply Chain Issues: Temporary supply constraints were experienced due to the transition to a contract manufacturer, affecting the ability to meet market demand.
Operating Loss: Despite a reduction in operating loss, the company still reported a GAAP operating loss of $4.9 million, indicating ongoing financial challenges.
Cash Management Risks: The company is working to improve predictability from Medicare Administrative Contractors (MACs) for claims processing, which is crucial for cash flow.
Leadership Transition: The upcoming leadership transition may pose risks related to strategic continuity and operational stability.
Profitable Revenue Growth: Q1 revenues were $5 million, down $300,000 year on year, but the business was up year on year. Key initiatives include FDA clearance of ReWalk 7, a partnership with CorLife, and expansion of MyoCycle distribution.
International Expansion: Contract with BARMER in Germany and partnerships with AlterG distributors, including four new business partners.
Sales Pipeline: Over 120 qualified ReWalk leads in the US pipeline, up over 70% from two quarters ago, and 36 ReWalk rentals underway, primarily in Germany.
Cost Management: Actions taken to reduce expenses, resulting in a 25% reduction in operating loss in Q1.
Leadership Transition: Smooth transition to a new CEO is underway, with a strong foundation built for future execution.
Revenue Guidance: Reaffirmed sales guidance of $28 million to $30 million for 2025.
Operating Loss Projection: Anticipation of a Q4 adjusted operating loss of approximately $1 million.
Gross Margin Expectations: GAAP gross margin was 42.2% in Q1 2025, with expectations for improvement as revenue grows.
Shareholder Return Plan: Lifeward Ltd. has not announced any specific share buyback program or dividend program during the Q1 2025 earnings call.
The earnings call highlights operational efficiencies and a strong pipeline, but concerns arise due to increased operating expenses and cash constraints. The Q&A reveals optimism in partnerships and revenue growth, yet lacks clarity on strategic execution. Despite the positive outlook, uncertainties in Medicare reliance and AlterG sales decline temper enthusiasm. The neutral rating reflects mixed signals, with potential growth balanced by financial and operational challenges.
Despite some positive developments, such as operational efficiencies and Medicare revenue growth, the earnings report reflects mixed signals. Revenue decline, increased GAAP operating expenses due to goodwill impairment, and lack of clear guidance on margin improvements counterbalance the positives. The Q&A further highlights concerns about tariff impacts, unclear margin improvements, and lowered guidance despite expected revenue growth. These mixed signals suggest a neutral market reaction.
The earnings call presents a mixed picture. Financial performance shows improvement in operating loss and gross margin, but revenue declined YoY. The Q&A reveals confidence in future growth, but uncertainties remain, especially with cash management and leadership transition risks. The lack of a shareholder return plan and ongoing financial challenges temper optimism. Positive aspects include improved margins and strategic partnerships, but these are offset by revenue decline and leadership risks, resulting in a neutral sentiment.
The earnings call reveals concerns over operational losses, declining margins, and a going concern qualification, which overshadow revenue growth. While product growth is anticipated, the significant operating losses and headcount reduction raise financial sustainability concerns. The Q&A highlights cautious guidance and uncertainty about new partnerships. Overall, negative sentiment due to financial health issues and lack of clear growth catalysts.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
